Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Judson

Showing results (71-80 of 111) with videos related to

Pageof 12
Sort By:
British Journal of Cancer|September 12, 2013
Trabectedin is a feasible treatment for soft tissue sarcoma patients regardless of patient age: a retrospective pooled analysis of five phase II trialsA L Cesne, I Judson, R Maki, et al.
The British Journal of Surgery|May 14, 2015
Surgical treatment of gastrointestinal stromal tumour of the rectum in the era of imatinibM J Wilkinson, J E F Fitzgerald, D C Strauss, et al.
European Journal of Cancer (Oxford, England : 1990)|August 17, 1999
Temozolomide in adult patients with advanced soft tissue sarcoma: a phase II study of the EORTC Soft Tissue and Bone Sarcoma GroupP J Woll, I Judson, S M Lee, et al.
Clinical Sarcoma Research|May 23, 2018
Aggressive fibromatosis response to tamoxifen: lack of correlation between MRI and symptomatic responseM Libertini, I Mitra, W T A van der Graaf, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 12, 2012
Chemotherapy treatment patterns and clinical outcomes in patients with metastatic soft tissue sarcoma. The SArcoma treatment and Burden of Illness in North America and Europe (SABINE) studyM Leahy, X Garcia Del Muro, P Reichardt, et al.
British Journal of Cancer|April 21, 2011
Performance status is the most powerful risk factor for early death among patients with advanced soft tissue sarcoma: the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (STBSG) and French Sarcoma Group (FSG) studyN Penel, M V Glabbeke, S Mathoulin-Pelissier, et al.
Lancet (London, England)|November 14, 2001
Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I studyA T van Oosterom, I Judson, J Verweij, et al.
British Journal of Cancer|October 14, 2005
A Phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end pointsA O'Donnell, A Padhani, C Hayes, et al.
British Journal of Cancer|September 1, 1999
Phase I and pharmacokinetic study of DACA (XR5000): a novel inhibitor of topoisomerase I and II. CRC Phase I/II CommitteeC J Twelves, C Gardner, A Flavin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 14, 2000
Phase I trial of 6-hour infusion of glufosfamide, a new alkylating agent with potentially enhanced selectivity for tumors that overexpress transmembrane glucose transporters: a study of the European Organization for Research and Treatment of Cancer Early Clinical Studies GroupE Briasoulis, I Judson, N Pavlidis, et al.
Pageof 12

Showing results (71-80 of 111) with videos related to

Sort By:
Pageof 12
British Journal of Cancer|September 12, 2013
Trabectedin is a feasible treatment for soft tissue sarcoma patients regardless of patient age: a retrospective pooled analysis of five phase II trialsA L Cesne, I Judson, R Maki, et al.
The British Journal of Surgery|May 14, 2015
Surgical treatment of gastrointestinal stromal tumour of the rectum in the era of imatinibM J Wilkinson, J E F Fitzgerald, D C Strauss, et al.
European Journal of Cancer (Oxford, England : 1990)|August 17, 1999
Temozolomide in adult patients with advanced soft tissue sarcoma: a phase II study of the EORTC Soft Tissue and Bone Sarcoma GroupP J Woll, I Judson, S M Lee, et al.
Clinical Sarcoma Research|May 23, 2018
Aggressive fibromatosis response to tamoxifen: lack of correlation between MRI and symptomatic responseM Libertini, I Mitra, W T A van der Graaf, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 12, 2012
Chemotherapy treatment patterns and clinical outcomes in patients with metastatic soft tissue sarcoma. The SArcoma treatment and Burden of Illness in North America and Europe (SABINE) studyM Leahy, X Garcia Del Muro, P Reichardt, et al.
British Journal of Cancer|April 21, 2011
Performance status is the most powerful risk factor for early death among patients with advanced soft tissue sarcoma: the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (STBSG) and French Sarcoma Group (FSG) studyN Penel, M V Glabbeke, S Mathoulin-Pelissier, et al.
Lancet (London, England)|November 14, 2001
Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I studyA T van Oosterom, I Judson, J Verweij, et al.
British Journal of Cancer|October 14, 2005
A Phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end pointsA O'Donnell, A Padhani, C Hayes, et al.
British Journal of Cancer|September 1, 1999
Phase I and pharmacokinetic study of DACA (XR5000): a novel inhibitor of topoisomerase I and II. CRC Phase I/II CommitteeC J Twelves, C Gardner, A Flavin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 14, 2000
Phase I trial of 6-hour infusion of glufosfamide, a new alkylating agent with potentially enhanced selectivity for tumors that overexpress transmembrane glucose transporters: a study of the European Organization for Research and Treatment of Cancer Early Clinical Studies GroupE Briasoulis, I Judson, N Pavlidis, et al.
Pageof 12